The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

Objective Tofacitinib, which is a Janus kinase (JAK) inhibitor, has shown clinical effects in the treatment of rheumatoid arthritis. JAKs are important kinases in lymphocyte differentiation; however, their function in dendritic cells (DCs) is unknown. In this study, the function of JAKs in DCs was i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2014-12, Vol.73 (12), p.2192-2198
Hauptverfasser:	Kubo, Satoshi, Yamaoka, Kunihiro, Kondo, Masahiro, Yamagata, Kaoru, Zhao, Jidong, Iwata, Shigeru, Tanaka, Yoshiya
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Apoptosis Autoimmune diseases B7-1 Antigen - drug effects B7-1 Antigen - immunology B7-2 Antigen - drug effects B7-2 Antigen - immunology Cell Differentiation - drug effects Cytokines Dendritic cells Dendritic Cells - drug effects Dendritic Cells - immunology Humans Immunoglobulins Interleukin-1beta - drug effects Interleukin-1beta - immunology Interleukin-6 - immunology Janus Kinase 3 - antagonists & inhibitors Kinases Lymphocyte Activation - drug effects Lymphocyte Activation - immunology Lymphocytes Piperidines - pharmacology Protein Kinase Inhibitors - pharmacology Pyrimidines - pharmacology Pyrroles - pharmacology Studies T-Lymphocytes - drug effects T-Lymphocytes - immunology Tumor Necrosis Factor-alpha - drug effects Tumor Necrosis Factor-alpha - immunology Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!